October 4, 2021

Because hypertension and wet age-related macular degeneration (AMD) are both found in elderly patients, their relationship is unclear. This study, published in Acta Ophthalmologica, attempted to analyze the association between hypertension and wet AMD and how their co-occurrence may impact wet AMD treatment strategies.  The study relied on electronic healthcare records from 2002 to 2019. A...

Anti-VEGF therapy is currently considered the most effective way to treat wet AMD but is highly burdensome for patients. Chitinase-3-like-1 (YKL-40) could serve as an alternative target for wet AMD treatment, as it has been shown to promote microangiogenesis and inflammation.  This study, published in FEBS Open Bio, investigated the role of YKL-40 in wet AMD....

The standard treatment for patients with wet AMD is antivascular endothelial growth factor therapy. Although effective, this treatment’s need for costly lifelong injections makes it less than ideal. Gene therapy for wet AMD can allow for the sustained delivery of antiangiogenic proteins, resulting in potentially less burdensome treatment for patients. This study, published in The British...

Although age-related cataracts and wet AMD co-occur in many patients, the timing of cataract surgery in patients with wet AMD is controversial. This article, published in Acta Ophthalmologica, analyzed the outcomes of patients with wet AMD who underwent cataract surgery. The study included 111 patients with a mean age of 78.9 ± 5.6 years. Both best-corrected...